A wide variety of antithrombotic P2Y12R antagonists such as ticlopidine (Ticlid), clopidogrel (Plavix), ticagrelor (Brilinta), prasugrel (Effient), ticagrelor (AR-C 69931),297 and MRS-2395298 have been developed for the treatment of platelet aggregation.269,299 Inhibition of the P2Y12R through knockdown of expression or by pharmacological inhibitor has resulted in less neuronal injury.294 The direct effects of the P2Y12 antagonists on cardiovascular system may indirectly heal neural injury and CNS diseases.16 Therefore, inhibition of both P2Y6 and P2Y12 receptors with their antagonists may prevent phagocytosis of salvageable cells and could be a promising path in treating neuroinflammation-induced neurodegeneration.251
